Cicognola, Claudia http://orcid.org/0000-0003-1806-7089
Janelidze, Shorena
Hertze, Joakim
Zetterberg, Henrik
Blennow, Kaj
Mattsson-Carlgren, Niklas
Hansson, Oskar
Funding for this research was provided by:
Vetenskapsrådet
Knut och Alice Wallenbergs Stiftelse
Marianne and Marcus Wallenberg Foundation
Alzheimerfonden
Hjärnfonden
Parkinsonfonden
ParkinsonFörbundet
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Region Skåne
Skånes universitetssjukhus
Bundy Academy
Thorsten och Elsa Segerfalks Stiftelse
Lund University
Article History
Received: 26 November 2020
Accepted: 9 March 2021
First Online: 27 March 2021
Declarations
:
: The study was approved by the Ethics Committee at the University of Lund and the patients and/or their relatives gave their informed consent (for research).
: Not applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS) (outside submitted work). OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche. The other authors declare no conflict of interest.